Literature DB >> 35665545

A Route to Lipid ALC-0315: a Key Component of a COVID-19 mRNA Vaccine.

Fariba Saadati1, Silvia Cammarone1, Marco A Ciufolini1.   

Abstract

This paper describes a synthesis of ALC-0315 by a sequence that more than doubles the overall yield relative to the published one, and that employs much cleaner reactions, thereby facilitating purifications to a considerable extent.
© 2022 Wiley-VCH GmbH.

Entities:  

Keywords:  RNA therapeutics; lipids; reductive amination; vaccines

Mesh:

Substances:

Year:  2022        PMID: 35665545      PMCID: PMC9348069          DOI: 10.1002/chem.202200906

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.020


Introduction

The compound known as ALC‐0315, 1 (Scheme 1), is a key lipid component of the Pfizer‐BioNTech COVID‐19 vaccine. Lipid nanoparticle (LNP) formulations of mRNA and siRNA containing 1 are also valuable research tools in the emerging field of nucleic acid therapeutics. Consequently, there is considerable interest in 1 on the part of research laboratories worldwide.
Scheme 1

Structure of ALC‐0315 and public‐domain synthesis thereof.

Structure of ALC‐0315 and public‐domain synthesis thereof.

Results and Discussion

A need for research quantities of 1 and congeners prompted us to duplicate the public‐domain synthesis, which is described in a patent, and that involves a double reductive alkylation of 4‐amino‐1‐butanol, 4, with aldehyde 3. The yield of 1 from 3 and 4 is reported to be of the order of 20 %. It rapidly transpired that the recorded procedure is fraught with extreme difficulties. First, aldehyde 3 is obtained by PCC oxidation of the corresponding alcohol 2. This step returns material contaminated with variable quantities of products of self‐condensation of 3. Conduct of the reductive amination step with impure aldehyde leads to the formation of myriad secondary products that complicate the purification of 1 to an unstainable degree. Aldehyde 3 thus requires careful, painstaking purification by column chromatography prior to reductive amination. Second, nonpolar 3 and highly polar 4 exhibit incompatible solubility properties. Aminoalcohol 4 is poorly soluble in solvents that readily dissolve 3 (hydrocarbons, CH2Cl2, CHCl3, THF), whereas 3 (cLogP ∼8!) is poorly soluble in media that dissolve 4 (e. g., MeOH, MeCN, DMF). Third, the reductive amination procedure described in the patent is carried out in CH2Cl2, in which 4 is poorly soluble, and in the presence of sodium triacetoxyborohydride, which is also poorly soluble in that solvent. The low instant solution concentrations of 4 and NaBH(OAc)3 translate into unusually slow rates of imine formation and reduction. As a consequence, the aldehyde and/or the imine survive long enough to undergo a multitude of self‐condensation reactions that generate a plethora of side products. The tedious chromatographic operations that are necessary to isolate the desired 1 lead to unacceptable losses, overall yields of 5–10 %, rather than 20 %, the consumption of large volumes of solvents and chromatographic supports, the generation of massive quantities of waste, and the expenditure of inordinate amounts of operator time. In our hands, the public‐domain avenue to 1 wasteful, impractical, and utterly unsustainable. This induced us to research alternative routes. The first objective of this investigation was to identify conditions for the preparation of 3 that would provide material of good quality, thus avoiding extensive chromatographic operations at the opening stages of the synthesis. The oxidation of alcohol 2 with activated DMSO (Parikh‐Doering, Swern ) returned cleaner aldehyde that was more readily purified. However, an operationally simpler TEMPO‐bleach oxidation in a biphasic CH2Cl2/aqueous medium gave the best results, affording the desired 3 in 90 % crude yield (Scheme 2). This material was obtained as a red oil. The origin of the color, which could not be removed by chromatography or by treatment with charcoal, remains unknown. However, the aldehyde appeared to be of very good quality and it was used in the reductive amination step without purification and without incident. On that note, the reductive amination of aldehydes tends to proceed best in halogenated solvents such as CH2Cl2 or (CH2Cl)2. Thus, a second objective was to identify a form of O‐protection that would render 4 soluble in CH2Cl2. Hanessian's tert‐butyl‐diphenylsilyl (TBDPS) group (cf. 5, Scheme 2) emerged as an excellent option.
Scheme 2

Preparation of compounds 3 and 5.

Preparation of compounds 3 and 5. Initial attempts to carry out the double reductive alkylation of 5 with 3 in CH2Cl2 under customary conditions (stirring a CH2Cl2 solution of 3, 5, AcOH, and NaBH(OAc)3 or NaBH3CN at 0 °C to room temperature) returned complex reaction mixtures consisting of comparable amounts of desired 1, alcohol 2 resulting from reduction of the aldehyde, plus a multitude of other substances. Mass spectral and NMR data suggested that a number of such byproducts were likely to be Chichibabin‐type pyridines and reduced forms thereof, signaling that the rate of reduction of iminium intermediates was too slow under the above conditions, probably because of the poor solubility of NaBH(OAc)3 or NaBH3CN in CH2Cl2 (the reaction is heterogeneous). The various iminium intermediates then become sufficiently long‐lived to undergo acid‐promoted (AcOH) self‐condensation reactions. Furthermore, the initial concentration of aldehyde must be too high relative to the instant concentration of imine/iminium species, translating into a great extent of reduction of 3 back to 2. Corrective measures thus aimed to (i) improve the solubility of the reducing agent in the reaction medium, and (ii) keep the instant concentration of aldehyde low. A solution to the first difficulty was sought in the form of a more CH2Cl2‐soluble acyloxyborohydride. Sodium tri(propionyloxy)‐borohydride proved to be the best option. Slow addition of 3 (syringe pump) to a now homogeneous CH2Cl2 solution of 5, AcOH, and NaBH(OOCEt)3 resulted in a much cleaner reaction. However, the extent of aldehyde reduction was still excessive, indicating that the concentration of reducing agent was now too high. Optimal results were ultimately obtained by slow (syringe pump), simultaneous addition of CH2Cl2 solutions of aldehyde and NaBH(OOCEt)3 to a CH2Cl2 solution of 5 and AcOH, whereupon 6 reproducibly emerged in 47–50 % yield after chromatography (Scheme 3). The synthesis was completed by desilylation of 6 with HF‐pyridine to give 1 in 82 % yield after chromatography. Lipid 1 is thus available in ca. 37 % overall yield from 4, the costliest starting material, through a linear sequence that encompasses 3 steps.
Scheme 3

Synthesis of ALC‐0315, 1.

Synthesis of ALC‐0315, 1. Parallel studies on the biological activity of LNP‐RNA formulation containing analogues of 1 revealed the desirability of a synthetic intermediate such as 11 (Scheme 4), which could be easily advanced to congeners of ALC‐0315 exhibiting alternative acyl portions. Compound 11 was prepared by reductive alkylation of 5 with the known 6‐acetoxyhexanal, 9. Thus, mono‐acetylation of economical 1,6‐hexanediol, 7, afforded a product mixture consisting largely of monoacetyl derivative 8, plus diacetylated product and unreacted 7. An aqueous wash of the reaction solution removed water‐soluble 7. Concentration left an oily residue consisting of an approximately 84 : 16 (1H NMR) mixture of 8 and the corresponding diacetate. The isolation of the desired 8 was greatly facilitated by its mediocre solubility in hexanes. Thus, washing the residue with hexanes removed most of the diacetyl product with marginal loss of 8, and left behind material containing no more than 3 % (1H, 13C NMR) of diacetate. Rough filtration through silica gel removed the last of the diacetate, and subsequent Kugelrohr distillation (75 °C) afforded pure 8 (76 %) a colorless oil. Oxidation by the TEMPO‐bleach method produced 9 in 91 % yield after Kugelrohr distillation. The product, a pale‐yellow oil, had excellent shelf life when stored at −20 °C. Multigram batches of 9 were thus prepared without difficulty and without chromatography. Reductive alkylation of 5 with 9 under the conditions described earlier consistently furnished 10 in 77–80 % yield after chromatography. Ensuing deacetylation gave diol 11 (quantitative), which can be advanced to ALC‐0315 and congeners by esterification followed by desilylation. This is exemplified in Scheme 4 by the conversion of 11 to 1. Thus, esterification with 2‐hexyldecanoic acid in the presence of EDCI delivered 6, which was desilylated with HF‐pyridine to give 1 in 57 % overall yield from 11 after column chromatography. Clearly, esterification of 11 with other acids would lead to analogues of 1.
Scheme 4

Synthesis of diol 11 and conversion thereof to 1.

Synthesis of diol 11 and conversion thereof to 1.

Conclusions

Relative to the public‐domain route, the syntheses just described (i) eschew the use of hazardous Cr(VI) reagents, (ii) are much higher yielding, (iii) suppress the need for early‐stage chromatography of aldehyde 3, and (iv) employ much cleaner reactions that minimize byproduct formation. This facilitates chromatographic purification of synthetic intermediates and final products to a great extent, realizing considerable economies in terms of solvents, chromatographic supports, and operator time. In addition, diol 11 can be converted into a variety of ALC‐0315 analogues, easing the study of the structure‐activity relationship of that remarkable lipid.

Conflict of interest

The authors declare no conflict of interest. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Supporting Information Click here for additional data file.
  3 in total

1.  Cu-catalyzed concise synthesis of pyridines and 2-(1H)-pyridones from acetaldehydes and simple nitrogen donors.

Authors:  Ziyuan Li; Xiaoqiang Huang; Feng Chen; Chun Zhang; Xiaoyang Wang; Ning Jiao
Journal:  Org Lett       Date:  2015-01-28       Impact factor: 6.005

2.  Enantioselective synthesis of 2,6-dideoxy carbasugars based on a desymmetrizing hydroformylation-carbonyl ene cyclization process.

Authors:  Bernhard Breit; Aurélien Bigot
Journal:  Chem Commun (Camb)       Date:  2008-11-11       Impact factor: 6.222

3.  A Route to Lipid ALC-0315: a Key Component of a COVID-19 mRNA Vaccine.

Authors:  Fariba Saadati; Silvia Cammarone; Marco A Ciufolini
Journal:  Chemistry       Date:  2022-07-04       Impact factor: 5.020

  3 in total
  2 in total

Review 1.  Application of lipid-based nanoparticles in cancer immunotherapy.

Authors:  Zhongkun Zhang; Siyu Yao; Yingwen Hu; Xiaobin Zhao; Robert J Lee
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

2.  A Route to Lipid ALC-0315: a Key Component of a COVID-19 mRNA Vaccine.

Authors:  Fariba Saadati; Silvia Cammarone; Marco A Ciufolini
Journal:  Chemistry       Date:  2022-07-04       Impact factor: 5.020

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.